TLX (Telix Pharmaceuticals) Institutional Ownership: 0.76% (As of Jul. 08, 2026)


TLX Telix Pharmaceuticals Ltd TLX
50 GF Score
Price $11.35
GF Value $30.73
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Institutional Ownership?

Telix Pharmaceuticals TLX -3.38% 50 Institutional Ownership is 0.76% as of Jul. 08, 2026. GuruFocus rates TLX with a GF Score™ of 50/100 and a GF Value™ of $30.73 (Possible Value Trap). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Telix Pharmaceuticals's institutional ownership is 0.76%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Telix Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Telix Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 92.30%.

Telix Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Telix Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals Institutional Ownership Chart

Telix Pharmaceuticals Historical Data

The historical data trend for Telix Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.04 0.08 0.08 0.15 0.15 0.17 0.29 0.32 0.60 0.60
TLX
50GF Score
Telix Pharmaceuticals Ltd TLX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telix Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.76% mean?
Telix Pharmaceuticals (TLX) has a Institutional Ownership of 0.76% as of Jul. 08, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Telix Pharmaceuticals and its competitors.
Is Telix Pharmaceuticals' Institutional Ownership too high?
Telix Pharmaceuticals' current Institutional Ownership is 0.76%. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Institutional Ownership compare to VRTX and REGN?
Telix Pharmaceuticals' Institutional Ownership of 0.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Telix Pharmaceuticals and its competitors. Telix Pharmaceuticals's current Institutional Ownership is 0.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $30.73, compared to a current price of $11.35 — trading 63.1% below its estimated fair value. The current Institutional Ownership is 0.76%. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current Institutional Ownership is 0.76% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Telix Pharmaceuticals (TLX) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of $11.35 is trading 63.1% below its estimated GF Value™ of $30.73. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TLX:

  • Institutional Ownership: 0.76%
  • GF Value™: $30.73 vs. price of $11.35 (63.1% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score

Get the complete analysis for TLX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.35
Price
$30.73
GF Value